LU91758I9 - - Google Patents

Info

Publication number
LU91758I9
LU91758I9 LU91758C LU91758C LU91758I9 LU 91758 I9 LU91758 I9 LU 91758I9 LU 91758 C LU91758 C LU 91758C LU 91758 C LU91758 C LU 91758C LU 91758 I9 LU91758 I9 LU 91758I9
Authority
LU
Luxembourg
Prior art keywords
receptors
isolated
inhibitors
screening
regulate
Prior art date
Application number
LU91758C
Other languages
English (en)
Other versions
LU91758I2 (fr
Inventor
Dirk M Anderson
Laurent J Galibert
Eugene Maraskovsky
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91758(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of LU91758I2 publication Critical patent/LU91758I2/fr
Publication of LU91758I9 publication Critical patent/LU91758I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU91758C 1996-12-23 2010-11-24 Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) LU91758I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5997896P 1996-12-23 1996-12-23
US7718197P 1997-03-07 1997-03-07
US6467197P 1997-10-14 1997-10-14
PCT/US1997/023775 WO1998028426A2 (fr) 1996-12-23 1997-12-22 Ligand pour l'activateur des recepteurs du nf-kappab, ligand membre de la superfamille de tnf

Publications (2)

Publication Number Publication Date
LU91758I2 LU91758I2 (fr) 2011-01-24
LU91758I9 true LU91758I9 (fr) 2019-01-02

Family

ID=27369779

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91758C LU91758I2 (fr) 1996-12-23 2010-11-24 Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)

Country Status (13)

Country Link
US (21) US6017729A (fr)
EP (5) EP2371962A3 (fr)
JP (7) JP4138013B2 (fr)
AT (2) ATE401404T1 (fr)
AU (2) AU713471C (fr)
CA (1) CA2274987C (fr)
DE (4) DE69740107D1 (fr)
DK (1) DK0951551T4 (fr)
ES (1) ES2144386T5 (fr)
IL (1) IL130492A (fr)
LU (1) LU91758I2 (fr)
PT (1) PT951551E (fr)
WO (2) WO1998028426A2 (fr)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050060764A1 (en) * 2003-09-17 2005-03-17 Susan Gregory Mouse model for bone metabolism
US6919434B1 (en) 1995-02-20 2005-07-19 Sankyo Co., Ltd. Monoclonal antibodies that bind OCIF
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
DE69738811D1 (de) 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
CA2274803C (fr) * 1996-12-23 2012-05-22 Immunex Corporation Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
NZ332995A (en) * 1997-04-15 2000-07-28 Snow Brand Milk Products Co Ltd A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (de) * 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
CA2229449A1 (fr) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Proteine receptrice nouvelle et son utilisation
WO1998054201A1 (fr) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Proteine 8 apparentee au recepteur du facteur de necrose tumorale humain
AU739304B2 (en) 1997-09-24 2001-10-11 Sankyo Company Limited Method of diagnosing metabolic bone diseases
WO1999029865A2 (fr) * 1997-12-12 1999-06-17 The Rockefeller University Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation
US7063960B2 (en) * 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) * 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
AU762574B2 (en) * 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
DK1114166T3 (da) * 1998-09-15 2005-08-01 Pharmexa As Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
IL145676A0 (en) 1999-04-12 2002-06-30 Genentech Inc Tumor necrosis factor homologs and nucleic acids encoding the same
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
US6872806B1 (en) * 1999-06-25 2005-03-29 The Governors Of The University Of Alberta Polypeptide compositions formed using a coiled-coil template and methods of use
EP2339003A3 (fr) 1999-06-28 2011-10-19 Genentech, Inc. Polypeptides variants substitutionnels du ligand Apo-2
ATE448781T1 (de) * 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) * 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
AU1920301A (en) * 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DE60134459D1 (de) * 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
EP1272647B1 (fr) 2000-04-11 2014-11-12 Genentech, Inc. Anticorps multivalents et leurs utilisations
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
IL153948A0 (en) 2000-07-27 2003-07-31 Genentech Inc Apo-2l receptor agonist and cpt-11 synergism
WO2002016551A2 (fr) * 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Regulation par trance de la differenciation des chondrocytes
WO2002015846A2 (fr) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anticorps monoclonaux à ligands anti-rank convenant au traitement de troubles à médiation des ligands des rank
DE01973455T1 (de) * 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
AU2002231602A1 (en) * 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
US20040132971A1 (en) * 2001-02-09 2004-07-08 Haaning Jesper Mortensen Rank ligand-binding polypeptides
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
EP1385532A4 (fr) * 2001-03-22 2004-12-15 Barnes Jewish Hospital Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank
IL157614A0 (en) * 2001-03-23 2004-03-28 Genentech Inc Uses of opg ligand to modulate immune responses
US20040167072A1 (en) * 2001-05-11 2004-08-26 Aggarwal Bharat B. Inhibitors of receptor activator of NF-kappaB and uses thereof
WO2002092623A1 (fr) * 2001-05-11 2002-11-21 Research Development Foundation Inhibiteurs de recepteur activateur de nf-$g(k)b et utilisations de ces inhibiteurs
ES2212930T1 (es) * 2001-05-17 2004-08-16 Immunex Corporation Uso terapeutico de antagonistas de rank.
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JP2005515159A (ja) * 2001-06-06 2005-05-26 イミュネックス・コーポレーション 癌を治療するためのｒａｎｋアンタゴニストの使用
EP1414517A4 (fr) * 2001-06-26 2008-02-06 Photomed Technologies Inc Illuminateur a longueurs d'onde multiples
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
CA2451680C (fr) 2001-07-03 2011-04-19 Genentech, Inc. Anticorps humains du dr4 et utilisations
US20030050223A1 (en) * 2001-08-09 2003-03-13 Jonathan Lam Crystal forms and mutants of RANK ligand
EP2348043A1 (fr) 2001-10-02 2011-07-27 Genentech, Inc. Variantes du ligand APO-2 et leurs utilisations
AU2002365426A1 (en) * 2001-10-12 2003-09-02 Barnes-Jewish Hospital Methods for screening osteogenic compounds
US20030100068A1 (en) * 2001-10-12 2003-05-29 Jonathan Lam RANKL mimics and uses thereof
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
CA2463649A1 (fr) * 2001-10-15 2003-04-24 Barnes-Jewish Hospital Mimetiques de rankl et utilisations de ceux-ci
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
WO2003042344A2 (fr) 2001-11-13 2003-05-22 Genentech, Inc. Formulations trail/ligand apo2
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
JP2005530482A (ja) * 2002-01-04 2005-10-13 ゼンコー・インコーポレイテッド ドミナントネガティブタンパク質およびそれらの用法
EP1560843A4 (fr) * 2002-01-04 2006-09-06 Xencor Inc Nouveaux variants de proteines rankl
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
US7381792B2 (en) * 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2003080671A1 (fr) * 2002-03-21 2003-10-02 Komed Co., Ltd. Anticorps monoclonaux anti-rank et compostion pharmaceutique contenant ceux-ci
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
EP2500032A1 (fr) 2002-06-24 2012-09-19 Genentech, Inc. Variantes du ligand/Trail APO-2 et leurs utilisations
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2003297833A1 (en) * 2002-12-10 2004-06-30 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
CA2512085C (fr) * 2003-01-10 2013-02-05 Protein Crystal Co., Ltd. Complexe de proteines, processus de fabrication et d'utilisation dudit complexe
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7700574B2 (en) * 2003-09-17 2010-04-20 Isis Pharmaceuticals, Inc. Modulation of RANKL expression
US7252833B2 (en) * 2003-11-18 2007-08-07 Skeletal Kinetics, Llc Calcium phosphate cements comprising an osteoclastogenic agent
JP2007517491A (ja) * 2003-12-29 2007-07-05 株式会社東京大学Ｔｌｏ 免疫調節剤を同定する方法、免疫調節剤、およびこれらの使用法
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
EP2292794A3 (fr) 2004-08-06 2011-07-06 Genentech, Inc. DR anticorps pour l'utilisation pharmaceutique et méthode utilisant des biomarqueurs pour prédire la sensibilité des cellules à lesdites anticorps
RU2431676C2 (ru) 2004-08-06 2011-10-20 Дженентек, Инк. Анализы и способы с применением биомаркеров
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101111522A (zh) * 2004-12-02 2008-01-23 杜门蒂斯有限公司 由于和功能域抗体缀合而具有提高的血清半衰期的plad功能域肽
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1915626B1 (fr) 2005-08-16 2011-11-09 Genentech, Inc. Sensibilite apoptotique a apo2/trail par essai d'expression de galnac-t14 dans des cellules/tissus
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
EP1854458A1 (fr) * 2006-05-08 2007-11-14 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation d'un composé avec activité RANKL
US8257933B2 (en) 2006-05-12 2012-09-04 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
CA2666415C (fr) 2006-10-11 2012-11-27 Oriental Yeast Co., Ltd. Reactif contenant une proteine fusionnee de rankl soluble avec un marqueur d'epitope
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
CA2685326A1 (fr) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Procede pour rapidement cribler des hotes microbiens et identifier certaines souches ayant un rendement et/ou une qualite d'expression des proteines heterologues ameliores
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US20100260680A1 (en) 2007-06-05 2010-10-14 Oriental Yeast Co., Ltd. Novel bone mass increasing agent
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
TWI595005B (zh) 2007-08-21 2017-08-11 安健股份有限公司 人類ｃ－ｆｍｓ抗原結合蛋白質
KR100911852B1 (ko) 2007-11-26 2009-08-11 고려대학교 산학협력단 유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
WO2009105934A1 (fr) * 2008-02-27 2009-09-03 上海先导药业有限公司 Anticorps monoclonal anti-rankl humain
CL2009001735A1 (es) 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
US8657662B2 (en) 2008-09-04 2014-02-25 Patent Investment & Licensing Company Gaming device having variable speed of play
US9435811B2 (en) 2008-09-30 2016-09-06 Oriental Yeast Co., Ltd Inducer of chondrocyte proliferation and differentiation
CN101712964B (zh) * 2008-10-08 2013-05-08 上海科新生物技术股份有限公司 抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
EP2376120A2 (fr) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Utilisation d'antagonistes dr6 et p75 pour favoriser la survie de cellules du systeme nerveux
CN101514232B (zh) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
KR101153393B1 (ko) * 2009-09-21 2012-06-07 고려대학교 산학협력단 점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
WO2011123813A2 (fr) 2010-04-02 2011-10-06 Amunix Operating Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
WO2012006635A1 (fr) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Molécules à chaîne unique pouvant être traitées et polypeptides faits à partir de celles-ci
EP2434285A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Diagnostic du cancer du sein
EP2433644A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Traitement du cancer du sein
US10047398B2 (en) 2010-10-06 2018-08-14 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2692359B1 (fr) 2011-03-31 2017-06-07 Oriental Yeast Co., Ltd. Potentialisateur d'immunité anticancéreuse contenant un antagoniste de rankl
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
FR2980711A1 (fr) * 2011-10-03 2013-04-05 Centre Nat Rech Scient Modulation du systeme immunitaire et des cellules stromales via rank
EP2776066B1 (fr) 2011-11-07 2018-09-19 Universite Laval Antagonistes de rank/rankl pour l'utilisation dans le traitement de troubles neuromusculaires, de myopathies génétiques et/ou de myopathies non génétiques
EP2650682A1 (fr) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Esters asymétriques d'acides gras utiles en tant que lubrifiants
JP6386450B2 (ja) 2012-06-06 2018-09-05 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 肺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
DK2906718T3 (da) 2012-10-12 2019-07-01 Inbiomotion Sl Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
JP6577873B2 (ja) 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） がんの転移の予後診断および処置のための方法
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CA2920376A1 (fr) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Procedes et composition comprenant du denosumab ou un anticorps ou un domaine, un fragment ou un derive associe de liaison a l'antigene, immunoreactif avec un peptide de recepteur activateur du ligand du facteur nucleaire kappa-b (rankl)/peptide de proteine de liaison d'osteoprotegerine (opgbp) destine a etre utilise dans le traitement, la
WO2015030701A1 (fr) * 2013-08-24 2015-03-05 R-Pharm Overseas, Inc. Anticorps entièrement humains contre le rankl humain
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US11427627B2 (en) 2013-09-05 2022-08-30 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA2926894A1 (fr) 2013-10-09 2015-04-16 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Methode de pronostic et de traitement d'une metastase cancereuse
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
CA2949237C (fr) 2014-05-16 2022-08-23 Amgen Inc. Dosage pour la detection de populations de cellules th1 et th2
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
RU2737496C2 (ru) 2015-04-29 2020-12-01 Радиус Фармасьютикалз, Инк. Способы лечения рака
CA2981115C (fr) * 2015-05-18 2022-05-31 Eli Lilly And Company Composes d'anticorps bispecifiques anti-dkk-1-anti-rankl
CN108064231A (zh) * 2015-05-20 2018-05-22 国立大学法人大阪大学 具有炎性细胞因子分泌抑制活性的寡肽
EP3400003B1 (fr) * 2016-01-05 2023-05-03 The Trustees of Columbia University in the City of New York Compositions pour la régulation de l'activité de l'inhibiteur de la protéine de liaison à l'adn de type 2 (id2)
WO2017123642A1 (fr) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Méthodes et utilisations du récepteur associé à l'ostéoclaste (oscar) pour la prévention et le traitement de l'arthrose
JP6815407B2 (ja) * 2016-02-01 2021-01-20 イーライ リリー アンド カンパニー 副甲状腺ホルモン−抗ｒａｎｋｌ抗体融合化合物
SG11201807596YA (en) 2016-03-08 2018-10-30 Janssen Biotech Inc Gitr antibodies, methods, and uses
KR102571924B1 (ko) 2016-05-25 2023-08-28 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
CN109890845B (zh) 2016-10-28 2022-07-01 伊莱利利公司 抗rankl抗体及其用途
FI3565542T3 (fi) 2017-01-05 2024-06-24 Radius Pharmaceuticals Inc Rad1901-2hcl:n polymorfisia muotoja
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
EP3713581A1 (fr) 2017-11-22 2020-09-30 Inbiomotion S.L. Traitement thérapeutique du cancer du sein basé sur le c-maf
IL313983A (en) 2018-03-26 2024-08-01 Amgen Inc Fully fucose-free glycoforms of antibodies are produced in cell culture
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl
WO2020070288A1 (fr) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et systèmes de contrôle des propriétés agonistes de domaines variables d'un anticorps par la lumière
MX2021005808A (es) 2018-11-20 2021-07-02 Univ Cornell Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
CA3152547A1 (fr) 2019-09-26 2021-04-01 Amgen Inc. Procedes de production de compositions d'anticorps
WO2021149012A1 (fr) 2020-01-24 2021-07-29 Radius Health, Inc. Méthodes de stimulation de la croissance osseuse faisant intervenir l'abaloparatide et le denosumab
CN111793135A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中rankl含量的抗体对及其用途
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (fr) 2020-10-15 2023-08-23 Amgen Inc. Glycanes relatifs non appariés dans des procédés de production d'anticorps
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
CA3233279A1 (fr) 2021-10-05 2023-04-13 Amgen Inc. Liaison de recepteur fc-gamma et teneur en glycane
WO2023179791A1 (fr) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Traitement de troubles musculo-squelettiques
WO2023198851A1 (fr) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Procédés de commande de la destruction de cellules tumorales par la lumière
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
EP0192658A4 (fr) 1984-07-30 1987-07-13 Salk Inst For Biological Studi Vecteurs retroviraux de transfert genetique.
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
DE3751997T2 (de) * 1986-07-18 1997-07-10 Univ Melbourne Aktives protein in humoraler hyperkalzemia, durch bösartigkeit verursacht
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
JP3356775B2 (ja) * 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US6121002A (en) * 1990-12-26 2000-09-19 The Rowett Research Institute Method to detect bone and other connective tissue disorders in humans and animals
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (fr) 1991-05-13 1992-11-14 Masahiko Sato Methode d'inhibition de la resorption osseuse
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
DK0822199T3 (da) * 1991-10-25 2004-12-27 Amgen Inc N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
PT639079E (pt) 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69427588T2 (de) * 1993-09-14 2002-04-25 Merck & Co., Inc. HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
EP0727211A1 (fr) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Emploi de composés spécifiques src SH2 dans le traitement de maladies de résorption osseuse
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (fr) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Recepteur humain du facteur de necrose tumorale
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
EP0822984A4 (fr) 1995-04-27 2000-05-03 Human Genome Sciences Inc Recepteurs du facteur de necrose tumorale chez l'homme
WO1997000317A1 (fr) 1995-06-07 1997-01-03 Osteosa Inc. Facteur regulateur de la croissance d'osteoclastes
WO1997000318A1 (fr) 1995-06-07 1997-01-03 Osteosa Inc. Facteur regulateur de la croissance des osteoplastes
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU693713B2 (en) 1995-06-07 1998-07-02 Immunex Corporation CD40L mutein
EP0835305B1 (fr) * 1995-06-29 2005-11-23 Immunex Corporation Cytokine inductrice d'apoptose
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
JPH0997808A (ja) 1995-09-29 1997-04-08 Mitsumi Electric Co Ltd ダイボンディング装置
JPH09151434A (ja) 1995-11-24 1997-06-10 Tootetsu:Kk 角形蛇籠の変形防止枠及びその蛇籠の設置方法
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
DK0873405T3 (da) 1996-01-11 2005-01-17 Immunex Corp Ekspressionsforøgende sekvenselementer (EASE) til eukaryote ekspressionssystemer
JPH09217897A (ja) 1996-02-14 1997-08-19 Hitachi Ltd Ｓｆ６貯蔵供給装置、その貯蔵方法及び供給方法
JPH09224803A (ja) 1996-02-21 1997-09-02 Nakajima Cafe Honsha:Kk 蓋付きコーヒーカップ
US5766223A (en) 1996-03-21 1998-06-16 Johnson; Deborah M. Child's teething device
US5710013A (en) 1996-04-19 1998-01-20 Tularik Inc. Tumor necrosis factor receptor associated factor 6 (TRAF6)
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
DE69738811D1 (de) * 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE69740107D1 (de) * 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
NZ332995A (en) 1997-04-15 2000-07-28 Snow Brand Milk Products Co Ltd A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
CA2229449A1 (fr) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Proteine receptrice nouvelle et son utilisation
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
WO1998054201A1 (fr) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Proteine 8 apparentee au recepteur du facteur de necrose tumorale humain
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO1999029865A2 (fr) 1997-12-12 1999-06-17 The Rockefeller University Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) * 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU762574B2 (en) * 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US6252180B1 (en) * 1999-08-09 2001-06-26 Lucent Technologies Inc. Electromagnetic interference cover for a conduit and an electronic equipment chassis employing the same
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
KR20010085996A (ko) 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
DE60134459D1 (de) 2000-02-23 2008-07-31 Amgen Inc Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002015846A2 (fr) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anticorps monoclonaux à ligands anti-rank convenant au traitement de troubles à médiation des ligands des rank
YU103003A (sh) * 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
MXPA04009681A (es) 2002-04-05 2005-01-11 Amgen Inc Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
US7157993B2 (en) 2003-09-30 2007-01-02 Rockwell Scientific Licensing, Llc 1:N MEM switch module

Also Published As

Publication number Publication date
ES2144386T9 (es) 2013-02-18
US20110086033A1 (en) 2011-04-14
EP2314695A2 (fr) 2011-04-27
WO1998028426A2 (fr) 1998-07-02
US6528482B1 (en) 2003-03-04
US6242213B1 (en) 2001-06-05
EP2371962A2 (fr) 2011-10-05
IL130492A (en) 2007-09-20
AU5618098A (en) 1998-07-17
US7744886B2 (en) 2010-06-29
US20110200990A1 (en) 2011-08-18
ATE497001T1 (de) 2011-02-15
DK0951551T4 (da) 2012-09-10
US6562948B2 (en) 2003-05-13
ES2144386T3 (es) 2009-01-16
US20120178912A1 (en) 2012-07-12
US20140186887A1 (en) 2014-07-03
EP0951551A2 (fr) 1999-10-27
US6419929B1 (en) 2002-07-16
US20080009014A1 (en) 2008-01-10
US8153775B2 (en) 2012-04-10
IL130492A0 (en) 2000-06-01
US8333963B2 (en) 2012-12-18
EP0946725A2 (fr) 1999-10-06
US20090017033A1 (en) 2009-01-15
ES2144386T1 (es) 2000-06-16
JP2008113656A (ja) 2008-05-22
DE69738841D1 (de) 2008-08-28
EP2371962A3 (fr) 2011-12-21
CA2274987C (fr) 2012-01-24
JP4138013B2 (ja) 2008-08-20
US6838262B1 (en) 2005-01-04
JP4242913B2 (ja) 2009-03-25
US20050003391A1 (en) 2005-01-06
JP2007014339A (ja) 2007-01-25
US8569456B2 (en) 2013-10-29
US7932375B2 (en) 2011-04-26
JP2010241823A (ja) 2010-10-28
AU5718498A (en) 1998-07-17
DK0951551T3 (da) 2008-09-01
ATE401404T1 (de) 2008-08-15
EP0951551B1 (fr) 2008-07-16
WO1998028424A2 (fr) 1998-07-02
EP2003203A1 (fr) 2008-12-17
US6537763B2 (en) 2003-03-25
DE122010000048I1 (de) 2011-05-05
US20020086827A1 (en) 2002-07-04
JP2008133302A (ja) 2008-06-12
JP2002509430A (ja) 2002-03-26
US6479635B1 (en) 2002-11-12
DE69740107D1 (de) 2011-03-10
JP2002509431A (ja) 2002-03-26
ES2144386T5 (es) 2012-12-07
US20020086826A1 (en) 2002-07-04
EP2314695A3 (fr) 2011-12-21
AU713471C (en) 2002-04-18
US6740522B2 (en) 2004-05-25
US20030175840A1 (en) 2003-09-18
JP4203105B2 (ja) 2008-12-24
EP0946725B1 (fr) 2011-01-26
EP0951551B9 (fr) 2012-12-26
US20140235832A1 (en) 2014-08-21
EP0951551B2 (fr) 2012-08-08
DE951551T1 (de) 2000-09-14
US7411050B2 (en) 2008-08-12
US8377690B2 (en) 2013-02-19
US20020081720A1 (en) 2002-06-27
US20120034690A1 (en) 2012-02-09
US6649164B2 (en) 2003-11-18
US6017729A (en) 2000-01-25
US20130203682A1 (en) 2013-08-08
US8715683B2 (en) 2014-05-06
CA2274987A1 (fr) 1998-07-02
AU713471B2 (en) 1999-12-02
LU91758I2 (fr) 2011-01-24
JP4054354B2 (ja) 2008-02-27
PT951551E (pt) 2008-10-28
US20020169117A1 (en) 2002-11-14
JP5096527B2 (ja) 2012-12-12
WO1998028424A3 (fr) 1998-09-11
AU713473B2 (en) 1999-12-02
US7262274B2 (en) 2007-08-28
JP2009051862A (ja) 2009-03-12

Similar Documents

Publication Publication Date Title
LU91758I9 (fr)
NZ306653A (en) Isolated dna il-17 receptors
HK1028417A1 (en) Cysteine rich receptors-train
YU15299A (sh) Farmaceutski sastavi
BG104236A (en) Transgenous mammals producing oligosaccharides in their milk
BR9710462A (pt) Naftopirans composicoes e artigos contendo as mesmas
EP0684086A3 (fr) Tri de courrier.
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
ZA9710593B (en) Antisebum and antioxidant compositions containing gugulipid and fractions thereof.
PL336470A1 (en) Mammalian cytokin-like factor 7
ZA976815B (en) Vaccine composition.
ITMI910697A1 (it) Apparecchio distruggi-documenti e recipienti come sottostruttura per il medesimo
HK58595A (en) Shampoo composition.
DE69001295D1 (de) In zufuhranlage niederschlaege kontrollierende zusammensetzungen.
IL99501A0 (en) Interleukin 9 receptors,methods for the use thereof and pharmaceutical compositions containing the same
EP0664115A3 (fr) Composition de shampoing.
BG100248A (en) Squalene synthetase inhibitors
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ZA975535B (en) Novel radiopharmaceutical compositions and matrices and the use thereof
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
BG104119A (en) A new composition
HRP970345A2 (en) Novel radiopharmaceutical compositions and matrices and the use thereof
ZA972708B (en) Pharmaceutical compositions and methods for the manufacture thereof.
IT246279Y1 (it) Guarnitura per mobili
EG19446A (en) Improved frog and method for the manufacture thereof.